Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Ramucirumab plus pembrolizumab improves OS in advanced NSCLC
Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL
Pre-operative risk factors associated with peri-operative psychiatric diagnosis in oral cancer patients
COMy 2022: Multiple myeloma roundup
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma
Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC
Recurrent non-invasive breast tumours may not always be related to the primary lesion
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects